Eli Lilly and Company (NYSE: LLY) stock closed at $1,044.67, down $13.51, or 1.28%, at 4:00 p.m. EST, before rebounding 0.46% to $1,049.17 in pre-market trading as of 4:34 a.m. EST. The sentiment around the stock remains firmly bullish as investors digest a major pipeline expansion announced late February 9. The pharmaceutical giant revealed it will acquire Orna Therapeutics in a deal valued at $2.4 billion, marking a strategic move beyond its blockbuster GLP-1 franchise into next-generation circular RNA therapies.
Despite the short-term dip, Eli Lilly stock continues to trade near record highs after briefly crossing a $1.01 trillion market capitalization milestone earlier this month, underscoring the market’s confidence in the company’s long-term growth trajectory.
Orna Therapeutics Acquisition Adds “Fresh” Pipeline Upside
The acquisition of Orna Therapeutics is the key piece of fresh news driving today’s Eli Lilly stock discussion. Orna is a biotechnology firm focused on circular RNA, a technology viewed as an evolution of traditional mRNA with potential advantages in durability, protein expression, and cell therapy applications. For Lilly, the deal broadens its innovation footprint beyond metabolic diseases into oncology, immunology, and regenerative medicine.
Commenting on the acquisition, Francisco Ramírez-Valle, M.D., Ph.D., Senior Vice President, Head of Immunology Research and Early Clinical Development, said, “We look forward to working with Orna colleagues to potentially unlock an entirely new class of genetic medicines and cell therapies for patients who today have limited or no treatment options.”
Management framed the Orna Therapeutics acquisition as complementary to Lilly’s existing research engine rather than a pivot away from GLP-1 drugs. Analysts largely agree, viewing the transaction as a strategic hedge that reduces long-term pipeline concentration risk while reinforcing Lilly’s reputation as an R&D leader.
GLP-1 Blockbusters Still Drive Financial Momentum
While circular RNA adds optionality, Lilly’s current financial strength is still anchored by its GLP-1 portfolio. Zepbound (tirzepatide), the company’s flagship weight-loss drug, generated approximately $4.3 billion in Q4 revenue, while Mounjaro (tirzepatide) delivered around $7.4 billion in the same period, benefiting from diabetes demand and off-label obesity use.
These figures keep Eli Lilly firmly ahead in the intensifying GLP-1 price war, even as rival Novo Nordisk continues to defend market share with Wegovy. Moreover, Lilly’s has projected 25% growth outlook, while Novo Nordisk’s is more cautious with its forward guidance.
Looking ahead, investor attention is also building around Orforglipron, Lilly’s oral GLP-1 pill, which is expected to receive regulatory approval in Q2 2026. If successful, Orforglipron could significantly expand access by eliminating injection-related barriers.
Guidance, Manufacturing, and Policy Tailwinds
Eli Lilly reaffirmed its full-year 2026 revenue guidance of $80 billion to $83 billion, alongside adjusted EPS expectations of $33.50 to $35.00. The company is also accelerating its manufacturing expansion, including a $3.5 billion facility in Pennsylvania, aimed at easing supply constraints for GLP-1 therapies and future RNA-based products.
On the policy front, ongoing discussions around Medicare obesity coverage and drug pricing, Donald Trump’s “TrumpRx” framework, remain a watch item for investors. While pricing pressure is a long-term risk, analysts note Lilly’s scale and manufacturing investments position it better than peers to absorb policy shifts.
Analyst Outlook Remains Strong
Wall Street remains constructive on Eli Lilly stock. Deutsche Bank recently raised its price target to $1,285, while Bernstein SocGen reiterated an Outperform rating with a $1,300 target. The broader consensus remains a Moderate Buy, reflecting confidence in Lilly’s diversified growth engine. In sum, while Eli Lilly stock may see near-term volatility, the Orna Therapeutics acquisition adds a new dimension to its story. With GLP-1 dominance, expanding manufacturing, and a growing presence in circular RNA, Lilly continues to be viewed as one of the most strategically positioned healthcare stocks in the global market.
